OncoResponse

OncoResponse presents Phase 1 trial results for **OR502**, an anti-LILRB2 antibody, in patients with advanced cancer. The findings will be highlighted as a late-breaker poster at the **39th Annual Society for Immunotherapy of Cancer (SITC)** conference on **November 9, 2024**. The trial evaluates safety and efficacy of OR502 as a potential immunotherapy for late-stage malignancies.

Nov 2024PR NewswireNews article

OncoResponse secures **$13 million** from the **Cancer Prevention and Research Institute of Texas (CPRIT)** and an additional **$14 million** from investors to develop **OR502**, a cancer immunotherapy. The funding supports clinical-stage research aimed at improving immune-based cancer treatments. The company now advances its pipeline with combined public and private capital.

May 2023PR NewswireNews article

OncoResponse presents three abstracts at the **Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting**, highlighting its immunotherapies derived from elite cancer responders. The company, based in Seattle, focuses on clinical-stage biotech solutions targeting cancer treatment. The presentations occur during the hybrid event in Washington D.C. and virtually from November 10–14, 2021.

Oct 2021PR NewswireNews article

OncoResponse secures **$40.6 million in Series C funding** to advance its lead antibody, **OR2805**, through **Phase 1 and 2 clinical trials**. The capital supports development of a potential immunotherapy targeting cancer treatment. The company’s pipeline focuses on precision oncology solutions.

Mar 2021BioSpaceNews article